Inflammatory bowel diseases
Cure8 research brief
Why This Matters
The analysis suggests that some biologic and small-molecule therapies work differently depending on whether Crohn's disease affects the ileum, colon, or both — information that could help tailor long-term treatment choices.
Who Should Pay Attention
Clinicians treating adults with moderate-to-severe Crohn's disease, researchers studying treatment heterogeneity or drug developers, and patients or caregivers interested in how disease location might influence long-term treatment response.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This paper pooled 18 randomized trials (≈4,700 patients) and focused on clinical remission (CDAI <150) and endoscopic response at about 52 weeks, analyzed by Montreal location. The key takeaway is that relative effectiveness of advanced therapies may vary by where Crohn's disease is located, which could be useful when choosing or sequencing treatments.
The findings do not prescribe specific treatment for an individual. They summarize trial-level data and report location-dependent differences for a subset of drugs rather than universal effects across all agents.
Clinical context: These results support considering disease location as one factor among many (prior treatment history, safety, comorbidities, patient preference) when making personalized treatment decisions.
Keep In Mind
This article is a systematic review and network meta-analysis of randomized trials with outcomes at ~52 weeks. It reports subgroup analyses by disease location using trial-level data; such analyses can be hypothesis-generating but may be limited by variations in trial design, patient populations, and numbers of patients in each location subgroup.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationInflammatory bowel diseases
AuthorsSóley Poulsen Dalsgarð, Kavini Kalinga Bandara Pkb, Jakob Benedict Seidelin +2 more
InstitutionDepartment of Gastroenterology and Hepatology, Copenhagen University Hospital-Herlev and Gentofte, DK-2730, Herlev, Denmark.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedOct 8, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
VIDEO: Longstanding therapies, recent approvals provide options in Crohn’s disease
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
Medical Therapies Beyond Infliximab for Perianal Fistulizing Crohn's Disease: Current Evidence and Future Perspectives.
Perianal fistulas are a common, hard-to-heal complication of Crohn's disease. This review collects current options beyond infliximab and explains where evidence is stronger or still emerging, which can help patients and...